Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NUVB is a good fit for your portfolio.
News
-
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
-
Thinking about buying stock in BigBear.ai, Bitfarms, Paysign, Nuvation Bio, or One Group Hospitality?
-
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
-
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
-
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Nuvation Bio Gets New Drug Application Clearance From FDA for Solid Tumor Treatment
Trading Information
- Previous Close Price
- $3.27
- Day Range
- $3.19–3.43
- 52-Week Range
- $0.95–4.16
- Bid/Ask
- $3.10 / $3.27
- Market Cap
- $794.47 Mil
- Volume/Avg
- 894,598 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.nuvationbio.com
Comparables
Valuation
|
Metric
|
NUVB
|
CLDX
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.17 | 5.54 | 11.32 |
Price/Sales | — | 299.58 | 10.90 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
CLDX
|
MRSN
|
|---|---|---|---|
Quick Ratio | 44.00 | 13.69 | 3.29 |
Current Ratio | 44.11 | 13.87 | 3.36 |
Interest Coverage | — | — | −44.11 |
Quick Ratio
NUVB
CLDX
MRSN
Profitability
|
Metric
|
NUVB
|
CLDX
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −8.79% | −30.49% | −49.57% |
Return on Equity (Normalized) | −9.03% | −33.19% | −211.52% |
Return on Invested Capital (Normalized) | −12.86% | −32.85% | −146.81% |
Return on Assets
NUVB
CLDX
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ngjmtpqlx | Dddr | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Txbtydn | Yzqql | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kvjbxdxl | Wpjcg | $103.7 Bil | |
MRNA
| Moderna Inc | Mwdgxwcwc | Zdz | $47.9 Bil | |
ARGX
| argenx SE ADR | Sppmmphw | Gmng | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Kxmcwngtz | Mrc | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xbdhpwk | Rdgljkc | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mvwdvpc | Mvfcx | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qdmkslfpdp | Vnptf | $12.8 Bil | |
INCY
| Incyte Corp | Jyfcrnqq | Sfdkn | $12.1 Bil |